tiprankstipranks
Trending News
More News >

Sichuan Kelun-Biotech Completes H Share Full Circulation

Story Highlights
  • Sichuan Kelun-Biotech completed the conversion of 25,421,196 domestic shares to H shares.
  • The conversion represents 11.19% of the company’s total share capital, enhancing market presence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Confident Investing Starts Here:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has successfully completed the conversion of 25,421,196 domestic shares to H shares, which will be listed on the Hong Kong Stock Exchange. This conversion represents approximately 11.19% of the company’s total share capital, marking a significant step in enhancing the company’s market presence and liquidity in the stock market.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of biopharmaceutical products. The company is involved in the biotechnology industry and operates with a market focus on innovative drug development and commercialization.

YTD Price Performance: 88.73%

Average Trading Volume: 616,642

Technical Sentiment Signal: Sell

Current Market Cap: HK$70.04B

For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App